

Direct Healthcare Professional Communication (DHPC) Date:

Date: 09th October 2026

[estradiol hemihydrate/levonorgestrel]

Important information regarding the use of the alternative name Estraseven Duo

50 micrograms/7 micrograms/24 hours, transdermal patches for FemSeven[®] Conti

50 micrograms/7 micrograms/24 hours, transdermal patch

Dear Healthcare Professional,

Summary

Gowrie Laxmico Limited, trading as B&S Healthcare in agreement with the Medicines and Healthcare products Regulatory Agency (MHRA) would like to inform you of the following:

- The parallel imported medicinal product will be marketed under the alternative name **Estraseven Duo 50 micrograms/7 micrograms/24 hours, transdermal patches**.
- **Estraseven Duo 50 micrograms/7 micrograms/24 hours, transdermal patches** is an authorised parallel version of **FemSeven[®] Conti 50 micrograms/7 micrograms/24 hours, transdermal patch**.
- The alternative name is being used solely for identification and marketing of the parallel import product.
- The introduction of the alternative name does not affect the product's composition, strength, pharmaceutical form, route of administration, indications, or dosing recommendations.
- **Estraseven Duo 50 micrograms/7 micrograms/24 hours, transdermal patches** is an alternative name applied to the parallel import licence product and should not be interpreted as indicating any difference in quality, safety, efficacy, or therapeutic effect compared with **FemSeven[®] Conti 50 micrograms/7 micrograms/24 hours, transdermal patch**.

Background

The use of an alternative name has the potential to cause confusion between products. This communication is intended to minimise the risk of medication errors by ensuring healthcare professionals are aware that Estraseven Duo 50 micrograms/7 micrograms/24 hours, transdermal patches is the authorised parallel import version of FemSeven[®] Conti 50 micrograms/7 micrograms/24 hours, transdermal patch.

A parallel import licence has been granted for Estraseven Duo 50 micrograms/7 micrograms/24 hours, transdermal patches, which corresponds to the medicinal product authorised and marketed in the UK as FemSeven[®] Conti 50 micrograms/7 micrograms/24 hours, transdermal patch.

The medicinal product marketed as Estraseven Duo 50 micrograms/7 micrograms/24 hours, transdermal patches contains the same active substance(s), strength, pharmaceutical form and route of administration as the reference product and has been authorised under the UK parallel import regulatory framework.

The alternative name does not indicate any difference in quality, safety, efficacy, therapeutic effect, formulation, strength, or approved use of the medicinal product when compared with the corresponding reference medicinal product.

Information for Healthcare Professionals

Healthcare professionals are requested to:

- Recognise Estraseven Duo 50 micrograms/7 micrograms/24 hours, transdermal patches as the authorised parallel import version of FemSeven® Conti 50 micrograms/7 micrograms/24 hours, transdermal patch.
- Ensure that prescribing, dispensing and administration processes correctly identify the product.
- Update local medicines information resources, formularies and electronic systems as appropriate.
- Inform relevant healthcare staff that the alternative name refers to the authorised parallel import product.
- Continue to use the medicine in accordance with the approved product information.
- Advise patients, where appropriate, that Estraseven Duo 50 micrograms/7 micrograms/24 hours, transdermal patches and FemSeven® Conti 50 micrograms/7 micrograms/24 hours, transdermal patch refer to the same medicinal product."

Call for Reporting

Please continue to report suspected adverse drug reactions (ADRs) to the MHRA through the Yellow Card scheme.

Please report:

- all suspected ADRs that are serious or result in harm. Serious reactions are those that are fatal, life-threatening, disabling or incapacitating, those that cause a congenital abnormality or result in hospitalisation, and those that are considered medically significant for any other reason
- all suspected ADRs associated with new drugs and vaccines identified by the black triangle ▼

You can report via:

- the [Yellow Card website](#)
- the free Yellow Card app available from the Apple App Store or Google Play Store
- some clinical IT systems (EMIS/SystemOne/Vision/MiDatabank) for healthcare professionals

Alternatively, you can report a suspected side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm.

When reporting please provide as much information as possible, including information about medical history, any concomitant medication, timing onset, treatment dates, and product brand name.

Company Contact Information

For further information regarding this communication, please contact:

GOWRIE LAXMICO LIMITED, TRADING AS B&S HEALTHCARE

Telephone: 0208-728-7661

Email: regulatorymodule1@bnsthamelabs.com

Yours faithfully,



Mustufa Zozwala

Team Leader

Gowrie Laxmico Limited, trading as B&S Healthcare